Latest news with #Guggenheim
Condé Nast Traveler
14 hours ago
- Entertainment
- Condé Nast Traveler
The Best Hotels in Bilbao, Northern Spain's Cultural Capital
Looking out towards the Guggenheim's sweeping titanium and glass frame, The Artist is a luxurious spot for any traveler fascinated by design. Originally called the Gran Hotel Domine, The Artist opened in 2002 and was designed by Spanish artists and architects Javier Mariscal and Fernando Salas, while Jeff Koons' floral 40-foot sculpture Puppy sits just outside the entrance. The airy lobby is dominated by the towering Fossil Cypress, an 85-foot column of rolled stone designed by Marisco that awkwardly soars up to the seventh (and top) floor. Speaking of the summit, it's The Artist's rooftop bar—imaginatively titled The Rooftop—that's perhaps most impressive here. While the view of the Guggenheim is obviously the star, the eye is also drawn to the lush hills and the distant hillside neighborhoods of Bilbao's extraordinary cityscape. Soak up the panorama with Idiazabal cheese, Iberico ham, and a glass of fruit-forward Rioja Crianza. Quality downstairs restaurant Olio and secret lobby cocktail bar Sixty One 61 form a fine gastronomic triumvirate. The hotel boasts 145 rooms, most of which exude a warm palette with bright midcentury lounging chairs but are thankfully restrained on the art, which is left to the public spaces. The sublime 861-square-foot penthouse comes with its own private terrace facing the museum. And to unwind, the oak-wood Turkish bath and sauna are perfect escapes from an admittedly tourist-heavy corner of Bilbao.
Yahoo
18 hours ago
- Business
- Yahoo
New Drug, New Direction: J&J Moves Deeper Into Late-Stage Therapeutics
Johnson & Johnson (NYSE:JNJ) is one of the . On July 21, 2025, J&J submitted a New Drug Application to the U.S. FDA for icotrokinra, an oral peptide therapy targeting moderate to severe plaque psoriasis in patients aged 12 and older—signaling a strong late‑stage R&D pipeline with growth potential beyond consumer staples or medtech divisions. On the analyst front, Guggenheim recently raised its price target from $164 to $167, while holding a Neutral rating in mid‑July 2025. The modest upgrade shows confidence in J&J's strategic balance between innovation and defensive income streams. Emilio100 / Despite being broadly diversified across consumer health, pharmaceuticals, and medical devices, J&J is relatively insulated from trade‑war volatility. Its supply chains are diffuse, production is localized in multiple markets, and it sources materials from global partners across regions less exposed to high tariffs. That allows J&J to preserve margin power and delivery continuity across geopolitical shifts. Johnson & Johnson is a global healthcare conglomerate spanning pharmaceuticals, medical devices, and consumer health products. Known for its scale and scientific depth, it operates in over 60 countries. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Business
- Yahoo
Eli Lilly (LLY) Gets Price Target Boost as Analysts See Strong Mounjaro, Zepbound Sales
Eli Lilly & Company (NYSE:LLY) ranks among the . On July 11, Guggenheim reiterated its Buy rating on Eli Lilly & Company (NYSE:LLY) ahead of the company's second-quarter earnings report and increased its price target from $936 to $942. Pixabay/Public Domain In contrast to the consensus predictions of $4.39 billion from VisibleAlpha and $4.89 billion from FactSet, the firm projects second-quarter Mounjaro sales of $4.49 billion. Guggenheim also predicts that Zepbound will rake in $3.10 billion in US sales in the second quarter, which is marginally more than the $2.94 billion consensus estimate. Guggenheim's modified model also takes into account a projected $0.14 effect on earnings per share from second-quarter IPR&D, as well as improved tirzepatide expectations based on prescription analysis. The firm also emphasized that investors are paying close attention to net price and prescription trends for tirzepatide, as well as a number of important clinical trial readouts scheduled through the end of 2025. Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world's largest pharmaceutical companies. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
a day ago
- Business
- Yahoo
GE Vernova hit with downgrades on its valuation after sharp rally
-- Mizuho and Guggenheim both downgraded shares of GE Vernova to Neutral given its stretched valuation following a roughly 90% rise this year. Though Mizuho raised its price target to $670 from $410, saying strong bookings in gas turbines and grid upgrades continue to drive earnings. But analysts at Mizuho believes much of the improvement is now reflected in the stock. The brokerage sees 2028 EBITDA reaching $10 billion, ahead of peers, but notes the stock trades at 16.7 times that estimate, slightly above industrial and AI-related peers. Guggenheim also downgraded the stock, saying even its above-consensus earnings forecasts no longer justify a Buy rating given the current price. While the firm still sees value over a longer time frame, it cited limited near-term upside and removed its $600 price target. 'Valuation is still admittedly attractive if investors are willing to focus on 2029 and beyond, but considering the wait required to get to that outcome, we no longer find GEV attractive from a risk/return standpoint,' analysts said Guggenheim said GE Vernova reported better-than-expected results for the second quarter and raised full-year guidance. Sales of aeroderivative turbines, used in data centers, accelerated during the quarter, while backlog growth suggests potential for production expansion beyond 2028. However, Mizuho said a formal announcement on capacity expansion is unlikely before late 2026. Related articles GE Vernova hit with downgrades on its valuation after sharp rally Analyst bullish on Texas Instruments on earnings lift as capex winds down Cisco upside now largely priced in, Evercore ISI downgrades stock Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. Global net revenues for the quarter for the Immunology portfolio rose to $6.264 billion, reflecting a growth of 16.6% on a reported basis or 18.1% on an operational basis. AbbVie Inc. (NYSE:ABBV) also experienced growth in global net revenues in the Neuroscience portfolio to $2.282 billion, reflecting a 16.1% increase on a reported basis or 17% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
